Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

MetEvoAMR

Financiado

The early metabolic stages in the evolution of antimicrobial resistance

Antimicrobial resistance (AMR) is a rising global health threat and rapid evolution of resistance against existing or newly developed antibacterial compounds is predicted to lead to 10 million deaths and $60 trillion of lost econo... ver más

28/02/2025

CHARITE UNIVERSIT...

174K€

Presupuesto del proyecto: 174K€

Líder del proyecto

CHARITE UNIVERSITAETSMEDIZIN BERLIN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2022-06-09

HORIZON-MSCA-2021-PF-01-01: MSCA Postdoctoral Fellowships 2021 ExpectedOutcome:

I+D

Cerrada hace 3 años

0% 100% 100%

1 Participantes

CHARITE UNIVERSITAETSMEDIZI...

173.85K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

PID2021-122705OB-I00 REDIRECCIONANDO EL DESCUBRIMIENTO DE ANTIMICROBIALES Y UTILI... 169K€ Cerrado

BIO2011-25255 INTEGRACION FISIOLOGICA DE LA RESISTENCIA A LOS ANTIBIOTICOS... 296K€ Cerrado

MAREE Mechanisms of Antibiotic Recalcitrance in ESKAPE pathogens 196K€ Cerrado

BES-2015-073164 COMBATIENDO LOS DETERMINANTES GENETICOS DE PAN-RESISTENCIA A... 93K€ Cerrado

BIO2014-51806-R COMBATIENDO LOS DETERMINANTES GENETICOS DE PAN-RESISTENCIA A... 212K€ Cerrado

IJC2019-038836-I Molecular basis of antibiotic resistance and interplay with... 93K€ Cerrado

Duración del proyecto: 32 meses Fecha Inicio: 2022-06-09
Fecha Fin: 2025-02-28

Líder del proyecto

CHARITE UNIVERSITAETSMEDIZIN BERLIN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 174K€

Descripción del proyecto Antimicrobial resistance (AMR) is a rising global health threat and rapid evolution of resistance against existing or newly developed antibacterial compounds is predicted to lead to 10 million deaths and $60 trillion of lost economic output by 2050. While resistance-conferring mutations, their inheritance and spread by horizontal gene transfer are increasingly well-studied, our understanding of pre-resistant cells’ survival and resilience in the presence of lethal antibacterial doses remains unclear. This proposal is stimulated by recent findings suggesting that the extracellular metabolic environment and metabolic adaptations play an overlooked role in transiently buffering antibiotic lethality and, therefore, increase the emergence of subpopulations of cells and their effective size that supports the evolution of antimicrobial resistance. In this proposal, I will systematically dissect mechanisms at work in subpopulations of pre-resistant cells of priority pathogens Pseudomonas aeruginosa and Acinetobacter baumannii that can transiently cope with antimicrobial treatment. I propose to combine my expertise in bacterial physiology with the Ralser Lab’s ultra-fast, massive-scale proteomics and phenomics technologies. I will systematically investigate the metabolic stress response in clinically relevant conditions, and identify the key metabolic and signalling processes that support the survival of subsets of challenged cells upon exposure to major classes of clinically applied antimicrobials. Finally, adaptive evolution experiments combined with CRISPR/Cas9 gene editing will validate causal effectors of identified tolerance mechanisms that precede the appearance of resistance-conveying adaptations. Here, I will acquire technical skills in innovative technologies and the host lab will benefit from my experience in working with pathogenic bacteria. I will lead public engagement efforts and disseminate scientific research outputs on an important global health issue.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores